Aytu BioPharma Q2 revenue beats expectations

Reuters

Feb 04

<a href="https://laohu8.com/S/AYTUZ">Aytu BioPharma</a> <a href="https://laohu8.com/S/QTWO">Q2</a> revenue beats expectations

Overview

Pharmaceutical company's Q2 revenue beat analyst expectations
Adjusted EBITDA for Q2 beat analyst expectations

Outlook

Company did not provide specific financial guidance for future quarters or full year in press release

Result Drivers

SHIFT IN MARKETING - Decreased net revenue from ADHD and Pediatric portfolios due to marketing focus shift to EXXUA
INVESTMENTS IN EXXUA - Significant investments in EXXUA launch impacted adjusted EBITDA, which still beat expectations

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Revenue	Beat	$15.17 mln	$12.17 mln (3 Analysts)
Q2 Net Income		-$10.58 mln
Q2 Adjusted EBITDA	Beat	-$800,000	-$4.30 mln (3 Analysts)
Q2 Gross Profit		$9.62 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00, about 195.2% above its February 2 closing price of $2.71

Press Release: ID:nACStMvP3a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608638826"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608638826\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608638826?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 05:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608638826","market":"us","top_or_hot":-1,"title":"Aytu BioPharma Q2 revenue beats expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/AYTUZ\">Aytu BioPharma</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue beats expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Pharmaceutical company's Q2 revenue beat analyst expectations</p></li><li><p>Adjusted EBITDA for Q2 beat analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific financial guidance for future quarters or full year in press release</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SHIFT IN MARKETING - Decreased net revenue from ADHD and Pediatric portfolios due to marketing focus shift to EXXUA</p></li><li><p>INVESTMENTS IN EXXUA - Significant investments in EXXUA launch impacted adjusted EBITDA, which still beat expectations</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Beat</p></td><td><p>$15.17 mln</p></td><td><p>$12.17 mln (3 Analysts)</p></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$10.58 mln</p></td><td></td></tr><tr><td><p>Q2 Adjusted EBITDA</p></td><td><p>Beat</p></td><td><p>-$800,000</p></td><td><p>-$4.30 mln (3 Analysts)</p></td></tr><tr><td><p>Q2 Gross Profit</p></td><td></td><td><p>$9.62 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00, about 195.2% above its February 2 closing price of $2.71</p></li></ul><p>Press Release: <span>ID:nACStMvP3a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aytu BioPharma Q2 revenue beats expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAytu BioPharma Q2 revenue beats expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-04 05:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/AYTUZ\">Aytu BioPharma</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue beats expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Pharmaceutical company's Q2 revenue beat analyst expectations</p></li><li><p>Adjusted EBITDA for Q2 beat analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific financial guidance for future quarters or full year in press release</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SHIFT IN MARKETING - Decreased net revenue from ADHD and Pediatric portfolios due to marketing focus shift to EXXUA</p></li><li><p>INVESTMENTS IN EXXUA - Significant investments in EXXUA launch impacted adjusted EBITDA, which still beat expectations</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Beat</p></td><td><p>$15.17 mln</p></td><td><p>$12.17 mln (3 Analysts)</p></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$10.58 mln</p></td><td></td></tr><tr><td><p>Q2 Adjusted EBITDA</p></td><td><p>Beat</p></td><td><p>-$800,000</p></td><td><p>-$4.30 mln (3 Analysts)</p></td></tr><tr><td><p>Q2 Gross Profit</p></td><td></td><td><p>$9.62 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00, about 195.2% above its February 2 closing price of $2.71</p></li></ul><p>Press Release: <span>ID:nACStMvP3a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nL1N3YZ1BB:1","article_id":"2608638826","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608638826","pubTimestamp":1770153700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aytu BioPharma Q2 revenue beats expectationsOverviewPharmaceutical company's Q2 revenue beat analyst expectationsAdjusted EBITDA for Q2 beat analyst expectationsOutlookCompany did not provide specific","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","AYTU":"Aytu BioScience, Inc."},"translate_title":"Aytu BioPharma第二季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AYTU":0.9},"content_text":"Aytu BioPharma Q2 revenue beats expectationsOverviewPharmaceutical company's Q2 revenue beat analyst expectationsAdjusted EBITDA for Q2 beat analyst expectationsOutlookCompany did not provide specific financial guidance for future quarters or full year in press releaseResult DriversSHIFT IN MARKETING - Decreased net revenue from ADHD and Pediatric portfolios due to marketing focus shift to EXXUAINVESTMENTS IN EXXUA - Significant investments in EXXUA launch impacted adjusted EBITDA, which still beat expectationsKey DetailsMetricBeat/MissActualConsensus EstimateQ2 RevenueBeat$15.17 mln$12.17 mln (3 Analysts)Q2 Net Income-$10.58 mlnQ2 Adjusted EBITDABeat-$800,000-$4.30 mln (3 Analysts)Q2 Gross Profit$9.62 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00, about 195.2% above its February 2 closing price of $2.71Press Release: ID:nACStMvP3aFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}